Cramer: Sell CytoKinetics, But Buy Celldex, Costco, and This Stock Instead
Jim Cramer made the following calls on July 1st, 2013. What do you think about his picks?
Cytokinetics Inc. (NASDAQ:CYTK): Jim Cramer ranked this stock a Sell. The stock’s 52-week high is $13.38, and its 52-week low is $3.48.
Cytokinetics is up almost triple over the last year, and despite its promising drugs in the realm of heart failure and skeletal muscle weakness, Cramer thinks its time to cash out and move on if you’re not already in the stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 19, 2013. The stock’s 52-week high is $16.89, and its 52-week low is $4.46.
Celldex is making head way into the realm of treating obscure diseases, as it begins testing a drug for the treatment of DDD, which is a rare ailment affecting the kidneys. The first patient has undergone dosage recently, and investors eagerly await results. However, Celldex is also up more than triple in the last year, making it an awkward time to buy for those interested. Cramer is persistent though, saying, “I like this one and I’m sticking with it.”
Costco Wholesale Corporation (NASDAQ:COST): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 10, 2013. The stock’s 52-week high is $115.77, and its 52-week low is $93.11.
Costco is known for giving great value to shoppers due to its business model, but Cramer thinks it can offer similar value to shareholders as well. Recent sales support that hypothesis, which were up 7 percent in May from last year.
CVS Caremark Corporation (NYSE:CVS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 4, 2013. The stock’s 52-week high is $60.70, and its 52-week low is $43.65.
Cramer prefers CVS to Walgreen (NYSE:WAG) since according to him, it’s “cheaper.” Reuters has also reported that CVS has considered taking a look at buying German drug company Celesio, joining a crowd of potential buyers.